(Q44788997)

6 December 2017

title

Multivariate analysis of survival in inflammatory breast cancer: impact of intensity of chemotherapy in multimodality treatment (English)

1 reference

6 December 2017

1 reference

multivariate statistics

1 reference

inflammatory breast cancer

inferred from title

1 reference

Bertucci F

1

1 reference

6 December 2017

Tarpin C

2

1 reference

6 December 2017

Charafe-Jauffret E

3

1 reference

6 December 2017

Bardou VJ

4

1 reference

6 December 2017

Braud AC

5

1 reference

6 December 2017

Tallet A

6

1 reference

6 December 2017

Gravis G

7

1 reference

6 December 2017

Viret F

8

1 reference

6 December 2017

Gonçalves A

9

1 reference

6 December 2017

Houvenaeghel G

10

1 reference

6 December 2017

Blaise D

11

1 reference

6 December 2017

Jacquemier J

12

1 reference

6 December 2017

Maraninchi D

13

1 reference

6 December 2017

Viens P

14

1 reference

6 December 2017

language of work or name

English

0 references

publication date

1 May 2004

1 reference

Bone Marrow Transplantation

6 December 2017

published in

1 reference

6 December 2017

volume

33

1 reference

6 December 2017

issue

9

1 reference

6 December 2017

page(s)

913-920

1 reference

Inflammatory breast cancer: a review

6 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704458

Prognostic factors in inflammatory breast cancer and therapeutic implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704458

Paclitaxel in the multimodality treatment for inflammatory breast carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704458

Distinct and complementary information provided by use of tissue and DNA microarrays in the study of breast tumor markers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704458

Lenograstim prevents morbidity from intensive induction chemotherapy in the treatment of inflammatory breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704458

First-line high-dose sequential chemotherapy with rG-CSF and repeated blood stem cell transplantation in untreated inflammatory breast cancer: toxicity and response (PEGASE 02 trial).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704458

Two distinct mechanisms alter p53 in breast cancer: mutation and nuclear exclusion

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704458

p53 mutations and overexpression in locally advanced breast cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704458

HER2 as a prognostic and predictive marker for breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704458

Oestrogen and progesterone cytosolic receptors in clinically inflammatory tumours of the human breast

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704458

Multimodality therapy in inflammatory breast cancer: is there a place for surgery?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704458

High-dose chemotherapy and stem-cell rescue in the treatment of high-risk breast cancer: prognostic indicators of progression-free and overall survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704458

Prognostic factors in inflammatory breast cancer. Univariate and multivariate analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704458

The Centre H. Becquerel studies in inflammatory non metastatic breast cancer. Combined modality approach in 178 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704458

Update on the management of inflammatory breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704458

Combined modality treatment of stage III and inflammatory breast cancer. M.D. Anderson Cancer Center experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704458

7 January 2021

Results of initial doxorubicin, 5-fluorouracil, and cyclophosphamide combination chemotherapy for inflammatory carcinoma of the breast

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704458

7 January 2021

Structure and expression of c-erbB-2 and EGF receptor genes in inflammatory and non-inflammatory breast cancer: prognostic significance

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704458

7 January 2021

Association of c-erbB2-gene amplification with poor prognosis in non-inflammatory breast carcinomas but not in carcinomas of the inflammatory type

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704458

7 January 2021

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704458

1 reference

7 January 2021

ERBB2 overexpression in breast carcinomas: no positive correlation with complete pathological response to preoperative high-dose anthracycline-based chemotherapy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704458

7 January 2021

Increased incidence of ERBB2 overexpression and TP53 mutation in inflammatory breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704458

7 January 2021

Prognostic value of p53 in breast invasive ductal carcinoma: an immunohistochemical study on 942 cases

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704458

7 January 2021

Tumor suppressor p53 mutations and breast cancer: a critical analysis

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704458

7 January 2021

Dose: a critical factor in cancer chemotherapy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704458

7 January 2021

Primary chemotherapy in the treatment of inflammatory breast carcinoma: a study of 230 cases from the Institut Gustave-Roussy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704458

7 January 2021

High-dose chemotherapy and haematopoietic stem cell transplantation for inflammatory breast cancer: pathologic response and outcome

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704458

7 January 2021

Management of inflammatory carcinoma of the breast with combined modality therapy including intraarterial infusion chemotherapy as an induction therapy. Long-term follow-up results of 28 patients

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704458

7 January 2021

Sixteen week dose intense chemotherapy for inoperable, locally advanced breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704458

7 January 2021

High-dose multimodality therapy with autologous stem-cell support for stage IIIB breast carcinoma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704458

7 January 2021

High-dose chemotherapy with peripheral blood stem cell support for stage IIIB inflammatory carcinoma of the breast

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704458

7 January 2021

Inflammatory breast cancer. Determination of prognostic factors by univariate and multivariate analysis

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704458

7 January 2021

Cell kinetics and hormonal receptor status in inflammatory breast carcinoma. Comparison with locally advanced disease.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704458

7 January 2021

High-dose chemotherapy with autologous hematopoietic stem-cell support for breast cancer in North America

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704458

7 January 2021

High-dose chemotherapy with autologous hematopoietic progenitor-cell support as part of combined modality therapy in patients with inflammatory breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704458

7 January 2021

Outcomes of high-dose chemotherapy and autologous stem-cell transplantation in stage IIIB inflammatory breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704458

7 January 2021

Identifiers

DOI

10.1038/SJ.BMT.1704458

1 reference

Dimensions Publication ID

6 December 2017

1035223181

0 references

1 reference